Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience-Reference-Cited by-同舟云学术

Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience

Published:2021-03 Issue:3 Volume:31 Page:869-879
ISSN:0939-4753
Container-title:Nutrition, Metabolism and Cardiovascular Diseases
language:en
Short-container-title:Nutrition, Metabolism and Cardiovascular Diseases

Author:

Scicali Roberto,Di Pino Antonino,Urbano Francesca,Ferrara Viviana,Marchisello Simona,Di Mauro Stefania,Scamporrino Alessandra^ORCID,Filippello Agnese^ORCID,Rabuazzo Agata M.,Purrello Francesco,Piro Salvatore

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Medicine (miscellaneous)

Reference58 articles.

1. Nonalcoholic fatty liver disease a systematic review;Rinella;J Am Med Assoc,2015

2. Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview;Marchisello;Int J Mol Sci,2019

3. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients;Targher;Diabetes Care,2007

4. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

5. Guidelines on the use of liver biopsy in clinical practice from the British society of gastroenterology, the royal college of radiologists and the royal college of pathology;Neuberger;Gut,2020

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A promising therapy for fatty liver disease: PCSK9 inhibitors;Phytomedicine;2024-06

2. Identification of key markers for the stages of nonalcoholic fatty liver disease: An integrated bioinformatics analysis and experimental validation;Digestive and Liver Disease;2024-06

3. Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome;European Cardiology Review;2024-05-09

4. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology;Atherosclerosis;2024-05

5. Altered lipid metabolism and the development of metabolic-associated fatty liver disease;Current Opinion in Lipidology;2024-03-15